Fintel reports that on October 20, 2023, Benchmark initiated coverage of Agilon Health (NYSE:AGL) with a Buy recommendation.
Analyst Price Forecast Suggests 51.44% Upside
As of October 5, 2023, the average one-year price target for Agilon Health is 29.29. The forecasts range from a low of 21.21 to a high of $43.05. The average price target represents an increase of 51.44% from its latest reported closing price of 19.34.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Agilon Health is 3,950MM, an increase of 7.63%. The projected annual non-GAAP EPS is -0.01.
What is the Fund Sentiment?
There are 518 funds or institutions reporting positions in Agilon Health. This is an increase of 7 owner(s) or 1.37% in the last quarter. Average portfolio weight of all funds dedicated to AGL is 0.31%, a decrease of 26.41%. Total shares owned by institutions increased in the last three months by 4.76% to 538,987K shares. 
The put/call ratio of AGL is 0.34, indicating a bullish outlook.
What are Other Shareholders Doing?
Clayton, Dubilier & Rice holds 100,000K shares representing 24.66% ownership of the company. In it's prior filing, the firm reported owning 194,611K shares, representing a decrease of 94.61%. The firm decreased its portfolio allocation in AGL by 49.22% over the last quarter.
Capital World Investors holds 51,348K shares representing 12.66% ownership of the company. In it's prior filing, the firm reported owning 42,436K shares, representing an increase of 17.36%. The firm decreased its portfolio allocation in AGL by 17.79% over the last quarter.
Wellington Management Group Llp holds 38,157K shares representing 9.41% ownership of the company. In it's prior filing, the firm reported owning 20,346K shares, representing an increase of 46.68%. The firm increased its portfolio allocation in AGL by 828.03% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 19,043K shares representing 4.70% ownership of the company. In it's prior filing, the firm reported owning 14,265K shares, representing an increase of 25.09%. The firm increased its portfolio allocation in AGL by 6.84% over the last quarter.
ANEFX - NEW ECONOMY FUND holds 17,247K shares representing 4.25% ownership of the company. In it's prior filing, the firm reported owning 14,503K shares, representing an increase of 15.91%. The firm increased its portfolio allocation in AGL by 5.40% over the last quarter.
Agilon Health Background Information
(This description is provided by the company.)
agilon health is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. agilon health enables physicians to create their own Medicare-centric globally capitated line of business. The agilon Total Care Model is powered by its purpose-built platform and enabled through a growing national network of like-minded physician partners. With agilon, physicians are freed from the constraints of the transactional fee-for-service reimbursement model and are able to practice team-based, coordinated care to serve the individual needs of their senior patients and to transition to a sustainable and predictable, long-term business model. The rapidly growing appeal of the agilon platform, partnership model and network of leading community-based physicians has allowed the company to expand to 17 local communities with 16 anchor physician groups, as well as a network of physicians across Hawaii, in fewer than five years.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
